10:19 AM EST - Sirona Biochem Corp. : Provided a corporate update from CEO Howard Verrico, regarding its plans both near and long term in the following Q&A format. Verrico says the pharmaceutical industry is highly competitive. Information on clinical development programs can be used strategically by other companies. Wanbang's team has shared all details of their program with us and Sirona is very pleased with the progress and dedication to the program. He urges investors to rest assured, Wanbang is moving efficiently with a comprehensive plan towards full CFDA approval of Wanpagliflozin (TFC-039) to provide a leading treatment option in China, the world's largest population of diabetic patients. Sirona Biochem Corp.
shares V.SBM are trading down $0.03 at $0.49.
